State of the Science Summit on Breast Cancer | Conference

NYU Langone's Perlmutter Cancer Center Buzzing With Breast Cancer Research

September 23rd 2019

Thought leaders from NYU Langone’s Perlmutter Cancer Center highlight the latest groundbreaking breast cancer research being conducted at their institution.

Tumor Biology Drives Personalized Surgical Interventions in Breast Cancer

September 17th 2019

Shubhada Dhage, MD, FACS, discusses the role of surgery and other therapeutic modalities in breast cancer and explained the shift toward de-escalated treatments and less morbid surgical management strategies.

Balancing Genomic and Clinical Risk in HR+ Breast Cancer

September 10th 2019

Nina D’Abreo, MD, explains how treatment is being tailored to women with early-stage, HR-positive, HER2-negative breast cancer.

Novel Approaches Push the Envelope in HER2+ Breast Cancer

September 9th 2019

Douglas K. Marks, MD, discusses key developments in the HER2-positive breast cancer space and shed light on novel approaches under investigation.

Dr. Marks on the Role of TKIs in HER2-Positive Breast Cancer

September 4th 2019

Douglas K. Marks, MD, clinical instructor, Department of Medicine, Perlmutter Cancer Center, NYU Langone Health, discusses the role of TKIs in HER2-positive breast cancer.

Dr. Novik on CDK4/6 Inhibitor Combinations in Breast Cancer

August 10th 2018

Yelena Novik, MD, associate professor, NYU Langone’s Perlmutter Cancer Center, discusses CDK4/6 inhibitor combinations in breast cancer.

Dr. Adams on Combinatorial Approaches in Triple-Negative Breast Cancer

August 1st 2018

Sylvia Adams, MD, associate professor, Department of Medicine, director, Clinical Research, Breast Cancer Disease Management Group, NYU Langone’s Perlmutter Cancer Center, discusses combinatorial approaches in triple-negative breast cancer.

Immunotherapy Remains Focal Point in TNBC

July 27th 2018

Sylvia Adams, MD, discusses the path forward for immunotherapy in triple-negative breast cancer.

Dr. Gerber on the Future Landscape of Radiation Oncology

July 25th 2018

Naamit K. Gerber, MD, assistant professor, Department of Radiation Oncology, NYU Langone’s Perlmutter Cancer Center, discusses the future landscape of radiation oncology.

Expert Sees Biosimilars as Integral to Expanding Access, Controlling Costs in Oncology

July 17th 2018

Yelena Novik, MD, shares her thoughts on the use of biosimilars in oncology and their potential impact on practice.

CDK4/6 Inhibitors Continue to Revolutionize ER+ Breast Cancer Care

July 16th 2018

Yelena Novik, MD, discusses the application of CDK4/6 inhibition and methods to overcome resistance in ER-positive breast cancer.

Dr. Novik on the Potential Impact of Biosimilars on Cancer Treatment

July 12th 2018

Yelena Novik, MD, associate professor, New York University’s Perlmutter Cancer Center, discusses the potential impact of biosimilars on the treatment of cancer.

Optimal Duration of Adjuvant Endocrine Therapy Undecided in ER+ Breast Cancer

July 10th 2018

Maryann J. Kwa, MD, discusses the optimal duration of endocrine therapy in the treatment of patients with early-stage ER-positive breast cancer.

Dr. Esteva on the Impact of the Trastuzumab Biosimilar Approval

July 7th 2018

Francisco J. Esteva, MD, PhD, medical oncologist, New York University’s Perlmutter Cancer Center, discusses the impact of the approval of the trastuzumab (Herceptin) biosimilar MYL-1401O (Ogivri; trastuzumab-dkst).

Esteva Recaps Advances in HER2-Targeted Therapy in Breast Cancer

July 6th 2018

Francisco J. Esteva, MD, PhD, discusses recent advances and clinical findings with HER2-targeted therapies across the neoadjuvant, adjuvant, and metastatic settings.

Dr. Kwa on the TAILORx Trial in Breast Cancer

July 5th 2018

Maryann J. Kwa, MD, instructor, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, discusses the results of the TAILORx trial in breast cancer.

Dr. Esteva Discusses Neratinib Updates in HER2+ Breast Cancer

July 4th 2018

Francisco J. Esteva, MD, PhD, medical oncologist, New York University’s Perlmutter Cancer Center, discusses updated neratinib (Nerlynx) data in patients with HER2-positive breast cancer.

Dr. Adams on Immunotherapy in Triple-Negative Breast Cancer

July 3rd 2018

Sylvia Adams, MD, associate professor, Department of Medicine, director, Clinical Research, Breast Cancer Disease Management Group, New York University Langone’s Perlmutter Cancer Center, discusses immunotherapy in triple-negative breast cancer (TNBC).

Dr. Novik on the Sustainability of Drug Development

June 29th 2018

Yelena Novik, MD, associate professor, New York University Langone’s Perlmutter Cancer Center, discusses the sustainability of drug development in oncology.

Dr. Gerber on Advances in Radiation Oncology in Breast Cancer

June 27th 2018

Naamit K. Gerber, MD, assistant professor, Department of Radiation Oncology, NYU Langone’s Perlmutter Cancer Center, discusses advances in radiation oncology in the treatment of patients with breast cancer.